A neuroscience paper recently published by Springer Nature's professional academic journal Nature Medicine said that the study found that a drug "Tilporide" (trade name: Mounjaro) used for diabetes and weight management can inhibit brain activity of people with uncontrolled eating behavior and reduce their desire for food for several months. This is the first human study on the effects of the weight loss drug tilpotide on brain activity, particularly in areas of the brain associated with pleasure, motivation, and reward. This paper introduces that the desire to eat, whether for pleasure or energy, requires complex interactions between different brain regions. GLP-1 receptor agonists such as tilpotide can promote weight loss, but their effects on regulating the brain network of eating disorders still need to be studied. Studying how these drugs can alter brain activity may help develop new potential therapies for unhealthy eating habits, related food overconfidence, and eating disorders. In this study, the corresponding author of the paper, Casey H. Halpern from the University of Pennsylvania in the United States, along with colleagues and collaborators, analyzed the brain activity of three subjects who were directly recorded with electrodes. These three subjects had severe obesity and had difficulty controlling their eating habits. They found that excessive attention and craving for food are associated with enhanced low-frequency brain signals (called delta theta activity) within the hypothalamus. Therapeutic deep brain stimulation of this brain region in two of the subjects can reduce this brain signal and attention to food, preliminarily confirming that it is a biomarker of excessive food attention and craving; The third subject used telpoleptide for diabetes management after weight loss surgery, which also realized the reduction of food cravings and weight loss; A previously implanted interface recorded a decrease in delta theta brain activity, but a few months later, when the person was still using a dose of tilboptin, these brain signals and subsequent food over attention reappeared. The author of the paper pointed out that the effect of tilpotide on excessive food attention may be related to the regulation of abnormal activity within the vagus barrier. These preliminary results are the first direct measurements of the vagus barrier activity in individual human study subjects using tilpotide, indicating that such drugs may reduce food cravings by affecting brain signaling biomarkers related to dietary control. The authors of the paper concluded that their research also highlights the therapeutic potential of these drugs for eating disorders, but further research is needed to analyze the relationship between tilpotide and food overconfidence as well as the brain. (New Society)